Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Portfolio Pulse from
Krystal Biotech announced promising early results from its KYANITE-1 study, showing that its inhaled KB707 treatment achieved a 27% objective response rate and a 73% disease control rate in heavily pre-treated patients with advanced non-small cell lung cancer.
December 18, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's inhaled KB707 treatment shows promising early results in NSCLC patients, potentially boosting investor confidence and impacting stock prices positively.
The announcement of positive early clinical results for KB707 in NSCLC patients is likely to boost investor confidence in Krystal Biotech's pipeline, potentially leading to a positive impact on the stock price. The 27% ORR and 73% DCR are significant indicators of the treatment's efficacy, which could attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100